Nabriva Therapeutics plc Long-Term Debt, Maturity, Year Four
Nabriva Therapeutics plc had Long-Term Debt, Maturity, Year Four of $1.35 million as of 2020-09-30, per its 10-Q filed 2020-11-05.
Discontinued › Notes › Commitment and Contingencies › Long-Term Debt, Fiscal Year Maturity › Long-Term Debt, Maturity, Year Four and Five
us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour · last filed 2020-11-05
- 2020-09-30: Long-Term Debt, Maturity, Year Four $1.35M.
- 2020-06-30: Long-Term Debt, Maturity, Year Four $1.35M.
- 2020-03-31: Long-Term Debt, Maturity, Year Four $1.35M.
- 2019-12-31: Long-Term Debt, Maturity, Year Four $11.89M.
| Period end | Long-Term Debt, Maturity, Year Four |
|---|---|
| 2020-09-30 | $1.35M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $1.35M 10-Q · filed 2020-08-06 |
| 2020-03-31 | $1.35M 10-Q · filed 2020-05-11 |
| 2019-12-31 | $11.89M 10-K · filed 2020-03-12 |
| 2019-09-30 | $17.45M 10-Q · filed 2019-11-12 |
| 2019-06-30 | $8.70M 10-Q · filed 2019-08-08 |
| 2019-03-31 | $8.70M 10-Q · filed 2019-05-10 |
| 2018-12-31 | $8.70M 10-K · filed 2019-03-12 |